SiNtx Technologies, Inc. - SINT STOCK NEWS

SINTX Technologies, Inc. (NASDAQ: SINT) announces the retirement of Chief Scientific Officer Dr. Bryan J. McEntire after 17 years. Dr. Ryan Bock, currently Director of R&D, will step in as Vice President of R&D, leading ongoing biomaterial development and expanding research on antipathogenic ceramics. Dr. McEntire has made significant contributions to the company, including research and product development for orthopedic implants made from silicon nitride. He will remain connected to SINTX in an advisory role.

SINTX Technologies recently provided a year-end business update, highlighting advancements in its biomedical, antipathogenic, and industrial segments. The company initiated joint research with leading universities under an NIH grant to develop 3D-printed silicon nitride PEEK composite spinal implants. New patent protections for antipathogenic applications offer potential commercial opportunities. Additionally, SINTX is constructing updates to its manufacturing facility for full production. Notably, the company received full forgiveness of a $509,148 SBA PPP loan, strengthening its financial position.

SINTX Technologies, Inc. (NASDAQ: SINT) announced the launch of its subsidiary SINTX Armor, signing a 10-year lease for a facility in Salt Lake City for development and manufacturing. The facility will house equipment moved from Dayton, OH, with construction updates underway to facilitate machine qualification starting December 2021. The new facility will produce advanced ceramic armor, including BoroShock and DuraShock, aimed at military and industrial applications. Revenue growth is anticipated in H2 2022 as production begins.

SINTX Technologies, Inc. (NASDAQ: SINT) announced the termination of its Patent License Agreement with O2TODAY due to delays in product development.

This follows SINTX's previous evaluation of joint efforts with O2TODAY, emphasizing its commitment to developing antiviral and antimicrobial fabrics using SINTX's patented FleX SN-AP silicon nitride powder. SINTX continues to pursue collaborations and product development in the antipathogenic fabric space, vital to its business strategy.

SINTX Technologies reported preliminary Q3 2021 revenue of approximately $240k, surpassing Q1 and Q2 revenues. Revenue stems from three sectors: spinal implants, antipathogenic fabrics, and armor. The company anticipates new revenue in Q4 2021 from open prototype orders for aerospace components and industrial applications. SINTX is focused on expanding its presence in advanced ceramics manufacturing at its FDA and ISO certified facility. A detailed business update will follow the upcoming Quarterly Report on Form 10-Q.

SINTX Technologies, Inc. (NASDAQ: SINT) announced the shipment of production quantities of a new porous, laser-textured monolithic silicon nitride implant for surgical spinal solutions. This shipment follows successful collaboration with CTL Amedica and supports a product launch expected in Q4 2021. The implants aim to enhance osseointegrative and antibacterial properties. SINTX has also submitted a provisional patent for improved manufacturing methods, supported by a Phase 1 grant from NIH. The company is actively investing in advanced manufacturing technologies and workforce recruitment.

SINTX Technologies has been awarded a $308,301 Phase 1 grant by the NIH to develop a 3-D printed silicon nitride – polyetheretherketone (SN-PEEK) spinal implant. This research focuses on enhancing the antibacterial and osseointegrative properties of silicon nitride. The project aims to capitalize on existing PEEK implant technology while integrating novel characteristics. Collaborating with notable universities, SINTX is positioned to advance spinal implant technology and plans to pursue a Phase 2 grant upon completion of this project.

SINTX Technologies held its annual meeting of stockholders on September 15, 2021, which was adjourned due to a lack of quorum. A majority of the outstanding shares entitled to vote was not present. The meeting is now rescheduled for October 13, 2021, at 10:30 a.m. MT. Stockholders of record as of July 26, 2021, are urged to vote by October 12, 2021. Approximately 44% of shares represented by proxies had been submitted. The company plans to further solicit votes and may incur additional costs if a quorum is not achieved at the adjourned meeting.

SINTX Technologies has established a new subsidiary, SINTX Armor, based in Salt Lake City, Utah, with plans to operate by the end of 2021. The company signed a decade-long lease for a facility that will focus on developing and manufacturing advanced ceramic armor, including boron carbide torso plates. This move aims to capture a share of the U.S. Department of Defense and law enforcement markets. SINTX has already shipped its first prototype order and aims to enhance innovation and operational efficiency in armor production.